SSWM
HAE icon

Sheets Smith Wealth Management’s Haemonetics HAE Stock Holding History

Sheets Smith Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,177
Closed -$591K – 297
2019
Q4 		$591K Buy
5,177
+10
+0.2% +$1.21K 0.11% 178
2019
Q3 		$652K Buy
5,167
+199
+4% +$25.3K 0.13% 164
2019
Q2 		$598K Buy
+4,968
New +$489K 0.12% 176

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Sheets Smith Wealth Management's HAE Position: Q1 2020 in Review

Sheets Smith Wealth Management sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 5,177 shares — an estimated $591K sold.

Sheets Smith Wealth Management first reported a position in HAE in Q2 2019 and held it in 3 quarters. The position peaked at $652K in Q3 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Sheets Smith Wealth Management reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 5,177 Haemonetics shares in Q1 2020, an estimated $591K.
  • Sheets Smith Wealth Management first reported a position in Haemonetics in Q2 2019 and held it in 3 quarters.
  • Sheets Smith Wealth Management's Haemonetics position peaked at $652K in Q3 2019.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Sheets Smith Wealth Management's 13F filing for Q1 2020, filed 28 Apr 2020.